Progress of network pharmacology-based research on Chinese medicine compounds for hyperuricemia

Hyperuricemia represents a prevalent metabolic condition characterized by dysregulated purine metabolism, culminating in excessive uric acid production.This pathology may progress to more serious complications, including gout.The United Nations has recognized hyperuricemia as one of the twenty major chronic diseases in the 21st century, reflecting its global impact.In China, the incidence of this disease has been rising, yet long-term treatment strategies and drug development continue to face challenges.Traditional Chinese Medicine (TCM) offers an alternative approach to managing hyperuricemia, boasting characteristics such as holistic treatment principles, adaptability, and reduced side effects compared to conventional Western therapies.Despite these benefits, the precise mechanisms underlying the efficacy of certain TCM compound treatments remain enigmatic.In the current clinical landscape, network pharmacology has emerged as a powerful tool to dissect the intricate interactions between drugs, diseases, and molecular targets.It provides a systems-level perspective, elucidating the "multi-component, multi-target, and multipathway" synergistic relationships inherent in TCM compound treatments.This integrative approach holds promise for enhancing our understanding of TCM's therapeutic effects and could pave the way for more refined and personalized treatment strategies in the management of hyperuricemia.The current studies on the use of network pharmacology in the treatment of hyperuricemia by using Chinese medicine compounding, elucidated the active ingredients, targets, biological processes and pathway analysis of the single drugs in Chinese medicine compounding, and explored the prospect of network pharmacology research with a view to better developing the application of Chinese medicine compounding in clinical practice.